BackgroundCheck.run
Search For

Garry W Larson, 791907 W Flamingo Ave UNIT 143, Nampa, ID 83651

Garry Larson Phones & Addresses

1907 W Flamingo Ave UNIT 143, Nampa, ID 83651    208-4660167   

Caldwell, ID   

Glendora, CA   

2515 Del Mar Ave, Pasadena, CA 91107    626-4493800   

4285 Lusitano Ave, Boise, ID 83713    208-9396787   

Enfield, CT   

Arcadia, CA   

Meridian, ID   

Temple City, CA   

Mentions for Garry W Larson

Publications & IP owners

Us Patents

Disease Association By Stratification

US Patent:
2002003, Mar 21, 2002
Filed:
Mar 5, 2001
Appl. No.:
09/797839
Inventors:
Theodore Krontiris - Pasadena CA, US
Garry Larson - San Dimas CA, US
Steven Flanagan - Running Springs CA, US
Assignee:
CITY OF HOPE - DUARTE CA
International Classification:
C12Q001/68
C07H021/02
C07H021/04
C12P019/34
US Classification:
435/006000, 435/091100, 435/091200, 536/023100
Abstract:
Pathogenetic allele variants that predispose to a disease can be identified by stratifying affected sib pairs by allele-sharing statuss at two or more candidate loci. This locus stratification method has been used to identify an allelic variant at the ATM locus which is implicated in breast cancer.

Inhibitors And Target Molecule Co-Localization

US Patent:
2003003, Feb 20, 2003
Filed:
Dec 17, 1999
Appl. No.:
09/465925
Inventors:
JOHN J. ROSSI - Rancho Cucamonga CA, US
GARRY P. LARSON - San Dimas CA, US
International Classification:
C12Q001/68
C07H021/04
A61K048/00
C12N015/85
C12P019/34
US Classification:
435/006000, 435/091310, 435/455000, 514/044000, 536/023100, 536/024500
Abstract:
The invention provides mechanisms for the co-localization in a living cell of a target molecule and of an inhibitor for the target molecule. The invention also provides novel chimeric tRNA-ribozyme molecules that compete effectively with tRNAfor HIV-1 reverse transcriptase binding sites. The chimeric human tRNA-ribozymes inhibit HIV reverse transcription by delivering inhibitors such as ribozymes of HIV-1 reverse transcriptase directly to the virion particle and render it non-functional. The chimeric molecules of the invention thus serve as highly specific non-toxic therapeutic agents and vaccines for viral, including lentiviral, infections. These chimeric molecules also reveal a novel, site specific RNA cleaving activity of HIV-1.

Chimeric Trna.sup.lys -Ribozyme Molecules

US Patent:
5827935, Oct 27, 1998
Filed:
Jan 24, 1994
Appl. No.:
8/185827
Inventors:
John J. Rossi - Glendora CA
Garry P. Larson - San Dimas CA
Assignee:
City of Hope - Duarte CA
International Classification:
C12N 1511
C07H 2104
C12Q 168
US Classification:
536 231
Abstract:
The invention provides novel chimeric tRNA. sup. LYS -ribozyme molecules that compete effectively with tRNA. sup. LYS for HIV-1 reverse transcriptase binding sites. The chimeric human tRNA. sup. LYS -ribozymes inhibit reverse HIV transcription by delivering inhibitors such as ribozymes of HIV-1 reverse transcriptase directly to the virion particle and render it non-functional. The chimeric molecules of the invention thus serve as highly specific non-toxic therapeutic agents. These chimeric molecules also reveal a novel, site specific RNA cleaving activity of HIV-1.

Disease Association By Locus Stratification

US Patent:
6248524, Jun 19, 2001
Filed:
Sep 28, 1998
Appl. No.:
9/161540
Inventors:
Theodore G. Krontiris - Pasadena CA
Garry P. Larson - San Dimas CA
Steven D. Flanagan - Running Springs CA
Assignee:
City of Hope - Duarte CA
International Classification:
C12Q 168
C12P 1934
C07H 2102
C07H 2104
US Classification:
435 6
Abstract:
Pathogenetic allele variants that predispose to a disease can be identified by stratifying affected sib pairs by allele-sharing statuss at two or more candidate loci. This locus stratification method has been used to identify an allelic variant at the ATM locus which is implicated in breast cancer.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.